Sarah Hughes

With celebrity chefs and travel gurus, Oceania Cruises is selling more than a vacation; it's selling curated connection. But does it deliver on the promise?

Barry Diller wants to buy MGM Resorts, a company where he's a director. Now, a legal probe is asking if the deal serves all shareholders or just one.

A deep dive into Toobit's H1 2026 report reveals a bold push into tokenized stocks and open-source AI, battling for market share with aggressive incentives.

AGNC Investment Corp. is a dividend machine, but with interest rates poised to rise, its upcoming earnings report is a stress test for income investors.

VMC Group's acquisition of a 108-year-old rival isn't just a transaction; it's a calculated move to dominate the unseen world of environmental control.

As corporate dentistry grows, a new integrated lab and purchasing module offers independent practitioners a fighting chance to streamline work and preserve autonomy.

As companies rush to deploy autonomous AI, a new partnership between HiddenLayer and Databricks aims to build the digital guardrails needed to prevent chaos.

A new report projects the soy protein isolate market will nearly double by 2036. But beyond the numbers lies a complex story of shifting diets, corporate races, and the fraught quest for a sustainable plate.

Vibrantz Technologies hires Garrett Gabel, a CFO with a deep restructuring background. The move signals a new era of intense financial discipline.

In one year, Abacus leaped from #20 to #3 on a key industry ranking. An inside look at the strategy of mergers and specialization that's redefining IT for finance and healthcare.

A small company claims it can turn municipal waste into green fuel at a disruptive price. With a major research firm's cautious nod, all eyes are on a small Portuguese port.

A tech certification may not sound like front-page news, but it signals a crucial step in healing the fragmented digital backbone of American healthcare.

A new patent in South Korea for a novel breast cancer vaccine offers a potential paradigm shift from treatment to prevention, but the road from patent to patient is long.

A $49M government-backed loan sends a Connecticut company’s stock soaring. Is this the future of American clean energy or a risky taxpayer-funded gamble?

A new AI tool promises to transcribe every word of an emergency call, turning chaos into data. But in a world of life and death, can we trust the algorithm?

For over a million Europeans with Parkinson's, a new drug promises longer periods of symptom control. But the path from regulatory approval to patient is complex.

uniQure's upsized $259M offering signals massive investor confidence, fueling its Huntington's therapy, AMT-130, and reshaping the gene therapy landscape.

Upper Deck's Space Jam anniversary isn't just nostalgia. It's a high-stakes playbook for how corporations are blending culture, sport, and collectibles.

As lawyers face massive sanctions for AI-fabricated citations, a new tool pits AI against AI to find the truth. But can we trust a machine to judge a machine?

The company once known for late-night snacks is pivoting hard, aiming to acquire a Taiwanese tech giant in a deal that could be worth over a billion dollars.